Fever News and Research

RSS

Mosquito borne Murray Valley Encephalitis warnings for NSW and North Victoria

The NSW Health authorities are warning residents and visitors in southern and western NSW to take extra precautions and protect themselves against mosquitoes following the detection of the Murray Valley Encephalitis (or MVE) virus in NSW. Residents and visitors to North Victoria are also similarly warned.

1 Jan 2012

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults

Pfizer Inc. announced today that the U.S. Food and Drug Administration has granted approval of the Company's pneumococcal conjugate vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) as a single dose for use in adults.

31 Dec 2011

Pioneer in infectious disease medicine shares his perspectives in new podcast series

Beginning this month, the journal Medicine launches a series of podcasts featuring pioneering infectious disease physician John Bartlett, MD. Medicine is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

28 Dec 2011

BBC News Magazine examines antiviral drug research

BBC News Magazine examines an antiviral drug called Draco, developed by Todd Rider, a research scientist at the Massachusetts Institute of Technology, "which has proven successful against all 15 viruses to which it has been applied in lab trials with human tissue and mice," including "the common cold, H1N1 or swine flu, a polio virus, dengue fever, and the notorious and fatal Ebola virus."

23 Dec 2011

Government, humanitarian agencies respond to flooding in Philippines, warn of disease threat

"Philippine authorities are warning of the spread of diseases in cramped evacuation centers, days after flash floods hit the southern Philippines and claimed more than a thousand lives," ABC/Asia Pacific News reports, noting that flooding also has affected the country's northern provinces, displacing at least 50,000 people.

22 Dec 2011

Study assesses evidence of immunosuppression in sepsis

An analysis of lung and spleen tissue from patients who died of sepsis revealed certain biochemical, cellular and histological findings that were consistent with immunosuppression, according to a study in the December 21 issue of JAMA.

21 Dec 2011

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB today announced the start of the EXXELERATE study which will evaluate the short- and long-term efficacy of Cimzia (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira(adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this study confirms previously announced plans.

21 Dec 2011

Yissum introduces novel technology for manufacturing an anti-malaria drug in tobacco

Combating malaria is one of the eight Millennium Development Goals described in the United Nations Millennium Declaration signed by all UN members at the year 2000. A key intervention to control malaria is prompt and effective treatment with artemisinin-based combination therapies.

19 Dec 2011

Affordable artemisinin using tobacco plants

19 Dec 2011

Pfizer enters Prevenar 13 supply agreement to protect children from pneumococcal disease

Pfizer Inc. today announced it has entered into a second supply agreement which will broaden and extend the duration of the Company's commitment to help protect millions of infants and young children in the developing world from pneumococcal disease - the leading cause of vaccine-preventable death in young children.

17 Dec 2011

Lab results change in consistent ways during the course of Kawasaki disease

Children with Kawasaki disease show a pattern of changing laboratory test results as the disease runs its course, according to a study in the December issue of The Pediatric Infectious Disease Journal.

15 Dec 2011

$Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL$

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

14 Dec 2011

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that updated data evaluating continuous treatment with REVLIMID (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology.

14 Dec 2011

Researchers discover how bloodstream malaria infection manipulates immune system

University of Iowa researchers and colleagues have discovered how malaria manipulates the immune system to allow the parasite to persist in the bloodstream. By rescuing this immune system pathway, the research team was able to cure mice of bloodstream malaria infections.

13 Dec 2011

Ruxolinitib reduces spleen size by 35% in patients with myelofibrosis

In a major advance in treatment, a multicenter study found that ruxolinitib did a better job than off-label chemotherapy drugs reducing the terrible symptoms associated with myelofibrosis, including pain, enlarged spleen, anemia, fever, chills, fatigue, and weight loss.

13 Dec 2011

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene International Sàrl, a subsidiary of Celgene Corporation, today reported final results from the phase II portion of a multi-center phase I/II study evaluating combination therapy with REVLIMID (lenalidomide) and VIDAZA (azacitidine) in patients with higher-risk myelodysplastic syndromes (MDS) not previously treated with either drug.

13 Dec 2011

Celgene announces interim results of REVLIMID study on CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

12 Dec 2011

Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting

Hematopoietic cell transplantation (HCT), the transplantation of blood-forming stem cells from the bone marrow, peripheral blood, or umbilical cord blood, is the primary option for treatment for many patients who suffer from various hematologic disorders, including blood cancers, sickle cell disease, bone marrow deficiencies, bleeding disorders, and autoimmune disorders. Research investigating breakthroughs in hematopoietic cell transplantation will be presented today at the 53rd Annual Meeting of the American Society of Hematology.

12 Dec 2011

Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced the initiation of two clinical studies for the nucleotide analogues ALS-2200 and ALS-2158, which are inhibitors of the hepatitis C NS5B polymerase.

12 Dec 2011

Experimental sublingual vaccine shows promise against influenza infection

Scientists from the International Vaccine Institute (IVI) have discovered that an antigen common to most influenza viruses, and commonly referred to as matrix protein 2 (M2), when administered under the tongue could protect mice against experimental infection caused by various influenza viruses, including the highly pathogenic avian H5 virus and the pandemic H1 ("swine flu") virus.

9 Dec 2011

Fever News and Research

Mosquito borne Murray Valley Encephalitis warnings for NSW and North Victoria

FDA approves Pfizer's Prevnar 13 pneumococcal conjugate vaccine as a single dose for adults

Pioneer in infectious disease medicine shares his perspectives in new podcast series

BBC News Magazine examines antiviral drug research

Government, humanitarian agencies respond to flooding in Philippines, warn of disease threat

Study assesses evidence of immunosuppression in sepsis

UCB initiates EXXELERATE study in rheumatoid arthritis

Yissum introduces novel technology for manufacturing an anti-malaria drug in tobacco

Affordable artemisinin using tobacco plants

Pfizer enters Prevenar 13 supply agreement to protect children from pneumococcal disease

Lab results change in consistent ways during the course of Kawasaki disease

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Researchers discover how bloodstream malaria infection manipulates immune system

Ruxolinitib reduces spleen size by 35% in patients with myelofibrosis

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene announces interim results of REVLIMID study on CLL

Breakthroughs in hematopoietic cell transplantation to be presented at 53rd ASH meeting

Alios BioPharma, Vertex initiate ALS-2200 and ALS-2158 clinical study in HCV

Experimental sublingual vaccine shows promise against influenza infection

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News